Literature DB >> 25152548

Response to High rates of death and hospitalization follow bone fracture among hemodialysis patients.

Francesca Tentori1, Keith McCullough2, Ryan D Kilpatrick3, Brian D Bradbury4, Bruce M Robinson5, Peter G Kerr6, Ronald L Pisoni2.   

Abstract

Entities:  

Year:  2013        PMID: 25152548      PMCID: PMC4141532          DOI: 10.1038/ki.2013.279.

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


× No keyword cloud information.
Response to Wakasugi et al. We thank Wakasugi et al., for their insights(1) regarding the rates of hip fracture among dialysis patients in Japan. Both theirs and our study highlights the substantial burden of fracture among dialysis patients relative to the general population, even after accounting for differences in case mix. The potential differences in the fracture rates reported by Wakasugi et al(2) compared to ours may be explained by a variety of factors, including differences in the study design and data collection. In the DOPPS, information on hospital admissions is collected through data abstraction from the patient medical record by a study coordinator, who is typically a nurse. The validity of this approach is supported by the fact that clinical outcomes collected in the DOPPS have been comparable to those reported by national registries(3). Data collection by Wakasugi et al. were based on patient recall (patient questionnaire), which may have contributed to the differences in fracture rates. Differences in the time period included for calculation may have also contributed, since even hip fracture rates in the Japanese general population varied substantially in reports from different time periods (4,5). Given the significant clinical burden associated with fractures in this frail population, additional studies examining fracture incidence and burden in Japanese dialysis patients may be warranted.
  3 in total

Review 1.  Random sample (DOPPS) versus census-based (registry) approaches to kidney disease research.

Authors:  Friedrich K Port; Robert A Wolfe; Philip J Held; Eric W Young
Journal:  Blood Purif       Date:  2003       Impact factor: 2.614

2.  Increased risk of hip fracture among Japanese hemodialysis patients.

Authors:  Minako Wakasugi; Junichiro James Kazama; Masatomo Taniguchi; Atsushi Wada; Kunitoshi Iseki; Yoshiharu Tsubakihara; Ichiei Narita
Journal:  J Bone Miner Metab       Date:  2013-01-06       Impact factor: 2.626

3.  Hip fracture incidence in Japan: estimates of new patients in 2007 and 20-year trends.

Authors:  Hajime Orimo; Yumi Yaegashi; Toshiyuki Onoda; Yasumasa Fukushima; Takayuki Hosoi; Kiyomi Sakata
Journal:  Arch Osteoporos       Date:  2009-10-02       Impact factor: 2.617

  3 in total
  5 in total

1.  Geovariation in Fracture Risk among Patients Receiving Hemodialysis.

Authors:  James B Wetmore; Jiannong Liu; Heidi S Wirtz; David T Gilbertson; Kerry Cooper; Kimberly M Nieman; Allan J Collins; Brian D Bradbury
Journal:  Clin J Am Soc Nephrol       Date:  2016-06-07       Impact factor: 8.237

Review 2.  Management of Secondary Hyperparathyroidism in Chronic Kidney Disease: A Focus on the Elderly.

Authors:  Andrea Galassi; Paola Ciceri; Eliana Fasulo; Stefano Carugo; Giuseppe Cianciolo; Mario Cozzolino
Journal:  Drugs Aging       Date:  2019-10       Impact factor: 3.923

Review 3.  Assessing bone mineralisation in children with chronic kidney disease: what clinical and research tools are available?

Authors:  A D Lalayiannis; N J Crabtree; M Fewtrell; L Biassoni; D V Milford; C J Ferro; R Shroff
Journal:  Pediatr Nephrol       Date:  2019-06-25       Impact factor: 3.714

4.  Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D.

Authors:  Takashi Hara; Yasukazu Hijikata; Yukiko Matsubara; Norio Watanabe
Journal:  Cochrane Database Syst Rev       Date:  2021-07-07

Review 5.  Bone Fragility in Chronic Kidney Disease Stage 3 to 5: The Use of Vitamin D Supplementation.

Authors:  Pablo Antonio Ureña Torres; Jean Claude Souberbielle; Martine Cohen Solal
Journal:  Metabolites       Date:  2022-03-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.